Theralase Technologies Inc.

PNK:TLTFF

$0.17 USD

$0.01 (3.03%)

Volume
51.8K
Average Volume
70.64K
Market Capitalization
$41.28M
P/E Ratio
-11.58
Dividend Yield
0.00%
Price Target
$
Year High
$0.27
Year Low
$0.08
Payout Ratio
$0.00
Current Ratio
$1.21

Industry, Sector & symbol

Stock Exchange Other OTC
CEO Mr. Roger John Dumoulin-White B.Sc., P.Eng.
Industry Medical - Devices
Sector Healthcare
Current Symbol TLTFF
CUSIP None
CIK None
Web https://www.theralase.com
Phone 416 699 5273
Currency USD
Employees 14
Country CA

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 1.21
Quick Ratio 0.77
Cash Ratio 0.29

Sales & Book Value

Annual Sales $1.07M
Price / Sales 52.98
Cash Flow -0.01
Price / Cash Flow -14.49
Price / Book 30.78

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.0208
Trailing P/E Ratio -11.58
PEG Ratio -5.73
P/E Growth -5.73
Net Income $-4.57M
Net Margin -478.72%
Pretax Margin -499.16%
Return on Equity -246.03%
Return on Assets -130.20%

Financials Score

AltmanZ Score -16.71
Piotroski Score 3.00
Working Capital 313.81K
Total Assets 3.38M
Ebit -4.4M
Market Cap 41.28M
Total Liabilities 1.73M

Poll Results

About Theralase Technologies Inc. (PNK:TLTFF) Stock

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by ... reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.

Theralase continued to advance bladder cancer study during Q3

2024-11-28 08:45:03

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) during the third quarter continued to make significant progress in its Study II clinical trial, which focuses on the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with a light-activated small molecule. The company reported that to date, 75 patients have been enrolled and treated, with the majority demonstrating promising outcomes.

Theralase(R) Release's 3Q2024 Financial Statements

2024-11-27 17:05:00

TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's unaudited condensed consolidated interim financial statements for the nine-month period ended September 30, 2024. (" Financial Statements ").

Theralase Technologies completes private placement to support Phase 2 bladder cancer study

2024-11-15 09:31:27

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has completed a non-brokered private placement, raising approximately $666,400 through the issuance of 2,221,334 units at $0.30 per unit. Each unit includes one common share and a warrant, allowing the purchase of an additional share at $0.45 within five years.

Theralase(R) Closes Non-Brokered Private Placement

2024-11-15 07:00:00

TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On closing, the Corporation issued an aggregate of 2,221,334 Units at a price of $CAN 0.30 per Unit for aggregate gross proceeds of approximately $CAN 666,400.

Theralase(R) Extends Warrants

2024-11-12 18:30:00

TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase® Technologies Inc. ("Theralase ®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,000,000 share purchase warrants ("Warrants") from November 17, 2024 to November 17, 2027. The Warrants were issued on November 17, 2022, pursuant to a private placement involving the issuance of 1,000,000 units of the Company.

Frequently Asked Questions

What is the current Theralase Technologies Inc. (TLTFF) stock price?

Theralase Technologies Inc.(PNK:TLTFF) stock price is $0.17 in the last trading session. During the trading session, TLTFF stock reached the peak price of $0.27 while $0.08 was the lowest point it dropped to. The percentage change in TLTFF stock occurred in the recent session was 3.03% while the dollar amount for the price change in TLTFF stock was $0.01.

TLTFF's industry and sector of operation?

The PNK listed TLTFF is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of TLTFF?

Mr. David M. Groves B.A | President of World Trade Division
Dr. Arkady Mandel DSc., M.D., Ph.D. | Chief Scientific Officer & Director
Ms. Kristina Hachey CPA | Chief Financial Officer & Director
Mr. Roger John Dumoulin-White B.Sc., P.Eng. | President, Chief Executive Officer & Director
Dr. Terry Ruch DVM | Equine Medical Consultant

How many employees does TLTFF have?

Number of TLTFF employees currently stands at 14. TLTFF operates from 41 Hollinger Road, Toronto, ON M4B 3G4, CA.

Link for TLTFF official website?

Official Website of TLTFF is: https://www.theralase.com

How do I contact TLTFF?

TLTFF could be contacted at phone #416 699 5273 and can also be accessed through its website. TLTFF operates from 41 Hollinger Road, Toronto, ON M4B 3G4, CA.

How many shares of TLTFF are traded daily?

The average number of TLTFF shares traded daily for last 3 months was 70.64K.

What is the market cap of TLTFF currently?

The market value of TLTFF currently stands at $41.28M with its latest stock price at $0.17